CBP-1019

N/A

Report date: 2024/07/03 15:55:00
NME

Base Information

Drug NameCBP-1019
Drug Alias NameCBP-1019
ClassificationSmall molecules > Synthetic peptide > Peptide drug conjugate (PDC)
Mechanisms of ActionDNA topoisomerase inhibitorsFolate receptor alpha modulatorsTransient receptor potential cation channel subfamily V member 6 modulators
TargetsDNA topoisomeraseFolate receptor alphaTransient receptor potential cation channel subfamily V member 6
Therapy Area/IndicationsSolid tumoursUrogenital NeoplasmsLung Neoplasms +[11] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesCoherent Biopharma Suzhou Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesCoherent Biopharma (Hefei) Co LtdThe University Of Texas MD Anderson Cancer CenterCoherent Biopharma Suzhou Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursUrogenital NeoplasmsLung Neoplasms +[10] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A